Navigation Links
Nastech to Present at Acumen BioFin Rodman & Renshaw Healthcare Conference
Date:10/31/2007

BOTHELL, Wash., Oct. 31 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK) announced today that it will present at the Acumen BioFin Rodman & Renshaw Healthcare Conference on Monday, November 5, 2007 at 2:40 p.m. Eastern Time at the New York Palace Hotel in New York City.

To access the live audio webcast for this conference, please log on to Nastech's website at http://www.nastech.com approximately 15 minutes prior to the presentation in order to register and download any necessary software. A replay of the audio presentation will be available following the event.

About Nastech

Nastech is a biopharmaceutical company developing innovative products based on proprietary molecular biology-based drug delivery technologies. Nastech and our collaboration partners are developing products for multiple therapeutic areas including osteoporosis, obesity, diabetes, autism, respiratory diseases and inflammatory conditions. Additional information about Nastech is available at http://www.nastech.com.

CONTACTS:

Nastech

Ed Bell

Director, Investor Relations

(425) 908-3639

ir@nastech.com

Russo Partners / LLC

David Schull (Media)

(212) 845-4271


'/>"/>
SOURCE Nastech Pharmaceutical Company Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
2. Wisconsin firms to present at Cleantech venture capital event
3. New Sonic Foundry search engine finds words, phrases in video presentations
4. Lone Wisconsin firm to present at InvestMidwest
5. Sonic Foundry creates search engine for 7,000 expert video presentations
6. InvestMidWest calls for business presentations
7. Wicab to present BrainPort at Boston conference
8. Three more Wisconsin firms to present at venture forum
9. Six Wisconsin firms to present at BIO Mid-America VentureForum
10. New Health and Human Services representative for Midwest
11. Top 20 big pharmas represent majority of world pharma market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Rockville, MD (PRWEB) September 17, 2014 ... Small Business Innovation Research (SBIR) grant to support the ... award will provide ITI with approximately $255,000 over one ... a leading cause of food allergy, affect over one ... anaphylaxis behind peanut allergy. Tree nut exposure is also ...
(Date:9/17/2014)... , Sept. 17, 2014 Intarcia Therapeutics, ... data from a study of the cost and predictability ... 50 th Annual Meeting of the European Association ... session today, Christian Frois , Ph.D., of Analysis ... series of planned Intarcia-sponsored, retrospective studies to characterize the ...
(Date:9/17/2014)... LAUDERDALE, Fla. , Sept. 17, 2014 Alternative ... an agreement to form a Special Purpose Vehicle in partnership ... based Jatropha centric agro energy company. The SPV shall be ... registered entity with AFAI as majority shareholder. The SPV shall ... Africa , particularly Ethiopia . ...
(Date:9/17/2014)... FRANCISCO, Calif. , Sept. 17, 2014 ... a molecular diagnostics company pioneering the field of molecular ... to chief operating officer. Mr. Hall joined ... the company,s commercial entry into endocrinology. Since 2012, he ... as well as managed care and billing functions. As ...
Breaking Biology Technology:Immunomic Therapeutics Awarded SBIR Grant to Develop Multi-Nut Allergy Immunotherapy 2Immunomic Therapeutics Awarded SBIR Grant to Develop Multi-Nut Allergy Immunotherapy 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 2Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 4Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 5AFAI Signs Joint Venture Agreement With Jatro Greentech Inc. 2AFAI Signs Joint Venture Agreement With Jatro Greentech Inc. 3Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 2Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 3Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 4
... DIEGO, March 16 Prometheus Laboratories Inc., a specialty ... received New York State approval for PROMETHEUS(R) IBS Diagnostic, ... syndrome (IBS). This novel test incorporates 10 biomarkers, ... algorithm to help physicians diagnose patients with IBS."One out ...
... N.J., March 16 DOR BioPharma, Inc. (OTC Bulletin ... it has appointed Gregg Lapointe, CPA, MBA, to its ... Executive Officer of Sigma-Tau Pharmaceuticals, Inc. (Sigma-Tau), a company ... patients with rare diseases. Sigma-Tau is DOR,s North American ...
... experts will address the benefits of rigorous early phase ... American Society for Clinical Pharmacology and Therapeutics (ASCPT), to ... Harbor, Maryland from March 18 - 21, 2009. The ... be to help biopharmaceutical companies understand best practice approaches ...
Cached Biology Technology:Prometheus Receives New York State Approval for PROMETHEUS(R) IBS Diagnostic, First Blood Test for Irritable Bowel Syndrome 2DOR BioPharma Appoints Gregg Lapointe, CPA, MBA, to its Board of Directors 2DOR BioPharma Appoints Gregg Lapointe, CPA, MBA, to its Board of Directors 3DOR BioPharma Appoints Gregg Lapointe, CPA, MBA, to its Board of Directors 4PAREXEL Experts to Address Benefits of Rigorous Early Phase Development at Annual ASCPT Meeting 2PAREXEL Experts to Address Benefits of Rigorous Early Phase Development at Annual ASCPT Meeting 3PAREXEL Experts to Address Benefits of Rigorous Early Phase Development at Annual ASCPT Meeting 4
(Date:9/17/2014)... Transmission of bacterial infections, including MRSA and MSSA ... microscopic bumps that mimic the scaly surface of ... open access journal Antimicrobial Resistance and Infection ... different materials prevented the spread of human disease ... named Sharklet, is an arrangement of ridges formulated ...
(Date:9/16/2014)... North American Menopause Society (NAMS) has published its ... midlife womenon everything from hot flashes to heart ... Society Recommendations for Clinical Care of Midlife Women," ... Menopause . This is the first, comprehensive ... midlife women freely available to all clinicians who ...
(Date:9/16/2014)... 36 Pit Fire began on September 13, 2014. The ... It is currently over 2,300 acres in size and is ... 36 Pit Fire was calm Monday night due to higher ... an anchor point and beginning to construct a fireline on ... following resources are working on the fire: , 7 20-person ...
Breaking Biology News(10 mins):Sharks' skin has teeth in the fight against hospital superbugs 2
... A new report demonstrates how a sensitive imaging ... bacteria in chronic infections. Listeria monocytogenes is ... illness and death. Listeria outbreaks recently claimed twenty ... most common cause of bacterial meningitis in newborns, and ...
... for simple taskswould have smiled at one of leptin,s mechanisms ... fat-derived hormone enlists the sympathetic nervous system to prevent bone-making ... discharge insulin. The study will appear online December 22, ... print issue of The Journal of Cell Biology ...
... the latest American Chemical Society (ACS) News Service ... journals and Chemical & Engineering News.,Please credit the ... the source for this information. ALL CONTENT ... is embargoed for 9 a. m., Eastern Time, ...
Cached Biology News:New research lights up chronic bacterial infection inside bone 2Leptin's long-distance call to the pancreas 2American Chemical Society's Weekly PressPac -- Dec. 17, 2008 2American Chemical Society's Weekly PressPac -- Dec. 17, 2008 3American Chemical Society's Weekly PressPac -- Dec. 17, 2008 4American Chemical Society's Weekly PressPac -- Dec. 17, 2008 5American Chemical Society's Weekly PressPac -- Dec. 17, 2008 6American Chemical Society's Weekly PressPac -- Dec. 17, 2008 7American Chemical Society's Weekly PressPac -- Dec. 17, 2008 8
... Zyagen tissue microarrays are derived from ... to rigorous quality control procedures to ensure ... are manually assembled in one block, sectioned ... mounted on coated slides. Sections are large ...
... microarrays are derived from frozen embedded tissue ... control procedures to ensure the highest quality. ... in one block, sectioned at a thickness ... slides. Sections are large (3-5 mm in ...
... microarrays are derived from Paraffin embedded tissue ... control procedures to ensure the highest quality. ... in one block, sectioned at a thickness ... slides. Sections are large (3-5 mm in ...
... are derived from frozen embedded tissue blocks, ... procedures to ensure the highest quality. Tissues ... one block, sectioned at a thickness of ... are large (3-5mm in diameter) in comparison ...
Biology Products: